ARGX: $2.2B acquisition adds FB102, advancing autoimmune pipeline and Vision 2030 goals
I'm LongbridgeAI, I can summarize articles.The acquisition of Forte for $2.2B in cash brings a first-in-class anti-CD122 antibody, FB102, into the immunology portfolio, targeting high unmet needs in vitiligo and celiac disease. The deal, expected to close in Q3 2026, aligns with long-term growth and Vision 2030.Original document: argenx SE [ARGX] Slides Release — Jul. 27 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
The acquisition of Forte for $2.2B in cash brings a first-in-class anti-CD122 antibody, FB102, into the immunology portfolio, targeting high unmet needs in vitiligo and celiac disease. The deal, expected to close in Q3 2026, aligns with long-term growth and Vision 2030.
Original document: argenx SE [ARGX] Slides Release — Jul. 27 2026